

R E M A R K S

The Final Office Action of August 14, 2001 presents the examination of claims 1-21. Claims 1-21 are indicated as allowable. Claim 22 is canceled herein, without prejudice to or disclaimer of the subject matter of the canceled claim, in order to advance prosecution of the present application. Applicants reserve the right to file an application directed to the subject matter of canceled claim 22 pursuant to 35 U.S.C. § 120.

The specification at pages 3 and 19 and claim 19 are amended to correct the molecular formula for saxitoxin. This amendment is of a minor editorial nature and merely reflects an inherent property of the named compound. As support for this proposition, Applicants note the description of saxitoxin at p. 1441 of the Merck Index, 12 Ed. (1996) (copy attached). Thus, no new matter is added to the application by any amendment herein. Unfortunately, the Bower paper cited in the specification appears to contain a typographical error in the formula for saxitoxin.

The favorable action of allowance of the application and its passage to issue are respectfully requested.


If the Examiner has any questions concerning this application, he is requested to contact Mark J. Nuell, Ph.D., Reg. No. 36,623, at (703) 205-8043.

Serial No.: 09/695,053

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Mark J. Nuell  
Reg. No. 36,623

P. O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

DRN/crt

VERSION SHOWING CHANGES MADE

**IN THE SPECIFICATION:**

The paragraph beginning on page 3, line 18 has been amended as follows:

--According to U.S. Patent No. 6,030,974, "saxitoxin" or "STX" refers to a compound comprising a tetrahydropurine moiety composed of two guanidine units fused together in a stable azaketal linkage, having a molecular formula  $C_{10} H_{[27]17} N_7 O_4 [1.2-HCl]$ , (mol. wt. 299.30) and to derivatives thereof, including but not limited to hydroxysaxitoxins and neosaxitoxin. See Bower et al., Nonprotein Neurotoxins, Clin. Toxicol. 18(7):813-863 (1981).--

The paragraph beginning on page 19 line 21 has been amended as follows:

Saxitoxin or STX refers to a compound comprising a tetrahydropurine moiety composed of two guanidine units fused together in a stable azaketal linkage, having a molecular formula  $C_{10} H_{[27] 17} N_7 O_2 [1.2-HCl]$ , (mol. wt. 299.30) and to derivatives thereof, including but not limited to hydroxysaxitoxins and neosaxitoxin. Bower et al., Nonprotein Neurotoxins, Clin. Toxicol. 18(7): 813-863 (1981).

**IN THE CLAIMS**

Claim 9 has been amended as follows:

19. (Amended) The method of claim 1, wherein the sodium channel blocking compound comprises a tetrahydropurine moiety comprising two guanidine units fused together in a stable azaketal linkage, having a molecular formula  $C_{10} H_{(27)17} N_7 O_4 [ \cdot 2-HCl ]$ , (mol. wt. 299.30) or a derivative[s] thereof.

Claim 22 is canceled.

## A Method of Local Anesthesia and Analgesia

Our Ref: A-LOC-002-E

Date Chinese application filed: April 26, 2001

5 Chinese application number: 01110498.8

### [Inventors]

10      *Name:*                      Yuling Liu  
         *Business address:* Department of Ophthalmology  
                                      Third Hospital, Peking University  
                                      Huayuan Beilu 49, Haidian District, Beijing  
                                      P.R. China 100083

15      *Citizenship:*              P.R. China

20      *Name:*                      Wenjuan Ying  
         *Business address:* Suit 901C, Beijing Huapu International Building  
                                      No. 19, Chaoyang Men Wai Street, Beijing  
                                      P.R. China 100020  
         *Citizenship:*              P.R. China

25

### [Assignee]

30      *Name:*                      Wex Medical Instrumentation Co., LTD.  
         *Address:*                Unit A, 34/F, Manulife Tower, 169 Electric Road, North Point, Hong  
                                      Kong

## A Method of Local Anesthesia and Analgesia

### FIELD OF THE INVENTION

5       The present invention relates to a method of obtaining local anesthesia and analgesia by administration of sodium channel blocking compounds, including tetrodotoxin and/or saxitoxin and derivatives thereof.

10

### BACKGROUND OF THE INVENTION

According to US Patent Application (09/702,826), pain is associated with actual or potential injury or tissue damage due to inflammation, ischemia, mechanical  
15 or other irritation. Local anesthetics are used to treat pain by blocking neuronal transmission and affect sensation as well as pain. Analgesics are used to relieve pain and they additionally may interfere with the activity of chemical mediators causing inflammation.  
20 Under regional anesthesia, patients remain conscious as the systemic physiological activity is exposed to minor interference, and few complications or commemorative signs are observed. Therefore, regional anesthesia is safe and comprehensively utilized in many surgeries.

25       Regional anaesthesia can be divided into various types, depending on the areas in which the anaesthetic is deposited and the techniques employed. Monheim divided regional anaesthesia into four kinds: (1) Topical (2) Infiltration, (3) Field Block and (4) Nerve Block.

In 1884, William S. Halsted demonstrated that the injection of a nerve trunk in any part of its course is followed by anaesthesia in its entire distribution.

Adams et al US Patent 4,029,793, 1977 states that  
5 tetrodotoxin has not found any practical use as an  
anesthetic. To the opposite, US Patent Application  
09/695,053 and 09/702,826 describe that tetrodotoxin can  
safely be used alone, or in combination with conventional  
anesthetics, to produce effective anesthesia or analgesia  
10 either systemically or locally. Particular examples of  
inhibiting cancer pain and blocking pain from dental pulp  
nerve respectively, are described.

In ophthalmic surgeries regional anesthesia is  
predominantly adopted because it is preferred by the  
15 patients and does not cause aftereffects that are  
commonly seen in systemic anesthesia, such as uneasiness,  
nausea and vomiting. Ophthalmic regional anesthesia is  
divided into three kinds:

20 1. Topical anesthesia: Dripping of a local  
anesthetic solution directly onto the surface  
of mucosa to anesthetize the sensory nerve  
endings. Topical anesthesia is adopted  
clinically for intraocular pressure  
measurement, gonioscopy and suture removal.

25 2. Infiltration anesthesia: Injection of an  
anesthetic into a tissue at a subcutaneous or  
deeper location so as to anesthetize the  
sensory nerve endings and fibers, such as  
subconjunctival anesthesia and orbicularis  
30 anesthesia.

3. Nerve block: Injection of an anesthetic into or  
around a nerve trunk so as to produce  
anesthesia in the distribution of the nerve  
trunk. Retrobulbar block, peribulbar block and  
5 facial nerve block are popular techniques in  
this category.

Anesthetics currently used, such as lidocaine and  
bupivacaine, may cause minor lesions, such that  
regeneration of the cornea epithelium could be inhibited.  
10 Current anesthetics also can produce further damage if  
they are used repeatedly, frequently or chronically.  
Where longer duration of anesthesia is required, more  
dosing might be necessary as some current anesthetics  
only provide brief action.

15 Therefore, there is a need in the art for methods of  
producing long lasting local anesthesia and analgesia  
without significant side effects.

Tetrodotoxin can be used as a local anesthetic and  
is ten thousand times more powerful than commonly used  
20 local non-narcotics, as is discussed by C.Y. Kao and F.A.  
Fulman, J. Pharmacol., 140, 31-40 (1965). Tetrodotoxin  
preparations in combination with other widely used  
anesthetics have been noted in U.S. Patent No. 4,022,899  
and U.S. Patent No. 4,029,793. According to U.S. Patent  
25 No. 6,030,974, "tetrodotoxin" or "TTX" refers to the  
amino perhydroquinazoline compounds having the molecular  
formula  $C_{11}H_{17}N_3O_8$  and to derivatives thereof, including  
but not limited to anhydrotetrodotoxin, tetrodaminotoxin,  
methoxytetrodotoxin, ethoxytetrodotoxin,  
30 deoxytetrodotoxin and tetrodonic acid (Kao, *supra*).



Examples of TTX analogs include novel TTX analogs isolated from various organisms, as well as those that are partially or totally chemically synthesized. See e.g., Yotsu, M. et al. Agric. Biol. Chem., 53(3):893-895, (1989). Such analogs bind to the same site on the alpha subunit of sodium channels as does TTX.

Adams, et al., U.S. Patent Nos. 4,022,899 and 4,029,793 describe a local anesthetic composition comprising a mixture in a pharmaceutically acceptable carrier of a particular toxin, namely tetrodotoxin or desoxytetrodotoxin, and another compound, generally a conventional local anesthetic compound or a similar compound having nerve-blocking properties. The conventional local anesthetic can be an aminoacylanilide such as lidocaine, an aminoalkylbenzoate such as procaine, cocaine, an amino carbamate such as dipiperodon, a N-phenylamidine such as phenacine, a N-aminoalkyl amide such as dibucaine, an aminoketone such as falicain, or an aminoether such as pramoxine.

U.S. Patent No. 6,030,974 describes a method of producing local anesthesia in a mammal experiencing pain in an epithelial tissue region. The method includes topically administering to the region, in a suitable pharmaceutical vehicle, an effective dose of a long-acting sodium channel blocking compound. The sodium channel blocking compound of U.S. Patent No. 6,030,974 can be a formulation of tetrodotoxin or saxitoxin at a concentration of between 0.001-10mM. The method described is classified as topical anesthesia in an epithelial tissue region, which is different from the

current invention which is a nerve block application. The invention is preferably applied in ophthalmic regional anesthesia. More preferably, the invention relates to retrobulbar injection of a local anesthetic that can  
5 block cranial nerve III, IV and V, ciliary ganglion and nerves, thus producing anesthesia in cornea, conjunctiva, iris, ciliary body and choroids, and deep narcosis of the eyeball. Meanwhile, the tension in the lateral rectus can also be reduced so as to decrease the intraocular  
10 pressure, allowing for a smooth surgery.

Zapata et al., Pain 72:41-49 (1997) discusses the utilization of tetrodotoxin for the inhibition of neuropathic ectopic activity in neuromas, dorsal root ganglia and dorsal horn neurons. The neuronal activity  
15 arises from neuroma caused by mechanical, chemical or ischemic injury. The effect of intravenously administered TTX on the neuronal induction by sciatic nerves in male rats was researched. However, the dosages and effects studied by Zapata et al. were applied to  
20 animals under anesthesia and artificial ventilation, thus these doses are above the maximal tolerated dose and the administration was under conditions that are not applicable to the presently intended clinical use of tetrodotoxin.

25 US Patent Application 09/702,826 provides a method of producing local analgesia and anesthesia in a mammal experiencing pain in a nerve tissue region. The method includes topically administering to the region, in a suitable pharmaceutical vehicle, an effective dose of a  
30 sodium channel blocking compound, including tetrodotoxin

and saxitoxin and their derivatives. A preferred nerve tissue region of that invention is a dental pulp region, a trigeminal nerve region or a sciatic nerve region. The effective dose is administered at a concentration of  
5 tetrodotoxin or saxitoxin ranging from 1 mM to 20 mM.

Local administration of any sodium channel blocking compound to the retrobulbar or peribulbar area of the eye is not described in any of the above instances.

#### 10 SUMMARY OF THE INVENTION

The present invention offers a solution to the need in the art for methods of producing a nerve block of long duration in ophthalmic surgeries. The inventors have demonstrated for the first time that sodium channel  
15 blocking compounds, such as tetrodotoxin and saxitoxin, can generate potent analgesic and anesthesia effects of long duration through retrobulbar or peribulbar block. The methods and compositions of the invention can be used for relevant ophthalmic surgeries or following injury to  
20 the eye. The methods present remarkable advantages, including providing from 30 minutes to 6 hours, preferably under 2 hours, of regional anesthesia and analgesia, without evident side effects.

According to reference [6], conventional synthetic  
25 local anesthetics block sodium channels by entering the nerve cell, and then block the channel from the inside. This is in contradistinction to tetrodotoxin, which blocks the sodium channel from the outside of the cell membrane. Synthetic local anesthetics are commonly  
30 classified into two major groups based upon whether the

intermediate chain is an ester or amide linkage. The main implications of this classification are that the routes of metabolism and the propensity for allergic reactions are predicted by the intermediate chain. The common  
5 esters are procaine, chlorprocaine, and tetracaine. The common amides are mepivacaine, prilocaine, lidocaine, bupivacaine and ropivacaine.

The present invention includes methods of producing local anesthesia and analgesia, comprising administering  
10 a pharmaceutically acceptable composition of a long-acting sodium channel blocking compound, wherein the compound binds to the extracellular mouth of the sodium channels, to a subject. Preferred compounds include toxins or analogs thereof that specifically bind to a  
15 site formed in part by an extracellular region of the alpha subunit of a sodium channel. Most preferred compounds comprise the class of toxins and analogs that specifically bind to a site formed by the SS1 and SS2 extracellular regions of the alpha sub-unit of a sodium  
20 channel, wherein such compounds include tetrodotoxin, saxitoxin and analogs thereof.

Accordingly, the present invention is intended to provide a method for producing local analgesia and anesthesia in patients experiencing pain such as that  
25 associated with damage to the eye.

One that is knowledgeable in the art will appreciate that retrobulbar or peribulbar injection of a same anesthetic such as the composition described in the current invention will both produce effective nerve block  
30 and immobilization.

In one aspect, the invention includes a method of producing local analgesia and anesthesia in the eye and surrounding facial tissues in a subject experiencing pain in the eye.

5       The method includes topically administering to the retrobulbar or peribulbar area, in a suitable pharmaceutical vehicle, an effective dose of tetrodotoxin or saxitoxin or analogs thereof.

10    BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a duration of action - dose relationship and an onset time - dose relationship of tetrodotoxin after administering to the retrobulbar region.

15    DETAILED DESCRIPTION OF THE INVENTION

As discussed above, the present invention provides a method of producing a local nerve block in the retrobulbar or peribulbar area by administering a  
20   anesthetically effective dose of a sodium channel blocking compound, typically tetrodotoxin.

Tetrodotoxin is a nonprotein neurotoxin that is found in multiple diverse animal species, including puffer fish, goby fish, newt, frogs and the blue-ringed  
25   octopus.

Saxitoxin is a compound comprising a tetrahydropurine moiety composed of two guanidine units fused together in a stable azaketal linkage, having a molecular formula  $C_{10}H_{17}N_7O_4$ . Saxitoxin is commercially  
30   available as a hydrochloride salt.

In the examples described herein, tetrodotoxin was administered locally to the retrobulbar or peribulbar area and found to provide potent long-acting pain relief with no signs of systemic or local toxicity. The method  
5 of the present invention addresses local analgesia and anesthesia for pain resulting from stimulation to ophthalmic nerves as a result of various ophthalmic diseases and ophthalmic surgery.

For the purpose of this application, a "nerve tissue  
10 region" is a portion of tissue that includes an anatomically identifiable nerve. Thus, a nerve tissue region can be tissue that includes the peribulbar or retrobulbar nerves, and the tissue that includes nerves distributed from the peribulbar or retrobulbar nerves.  
15 Another example of a nerve tissue region is the tissue through which the cranial nerve III, the cranial nerve IV or the cranial nerve V runs, and tissue that contains nerves that are distributed from these cranial nerves. Another example of a nerve tissue is ciliary ganglion and  
20 nerves that distribute therefrom.

Tetrodotoxin useful in the method of the present invention can be obtained from puffer fish organs. A detailed description of production of tetrodotoxin and derivatives thereof is provided in the Chinese patent  
25 application no. 00124516.3, filed September 18, 2000 corresponding to co-pending U.S. patent application number 09/695,711 filed October 25, 2000 and in Chinese patent application no. 00132673.2 filed November 22, 2000 corresponding to copending U.S. patent application number  
30 09/818,863 filed March 28, 2001.

Anesthesia of iris, cornea, conjunctiva, ciliary body and choroids is required in most intraocular surgeries, such as:

- extraction of cataract,
- 5       • intra-ocular implantation of artificial lens,
- vitrectomy,
- extraction of intra-ocular foreign body,
- and operation for retinal detachment.

Regional anesthesia by retrobulbar or peribulbar  
10 block is adopted in a majority of those surgeries where it is further required that the lateral rectus be immobilized completely.

Retrobulbar injection of a local anesthetics can block cranial nerve III, IV and V, ciliary ganglion and  
15 nerves, producing anesthesia in cornea, conjunctiva, iris, ciliary body and choroids, and deep narcosis of the eyeball. Meanwhile, the tension in the lateral rectus can also be reduced so as to decrease the intraocular pressure, allowing for a smooth surgery.

20       At present anesthetics used in ophthalmic operations include lidocaine, procaine, bupivacaine and etc. Lidocaine was introduced in 1944 and became a popular anesthetic in various operations. It features a rapid onset about 2 minutes, sound safety, and low possibility  
25 of inhibiting the cardiovascular system. It can produce over 20 minutes of duration of action in ophthalmic operations, making it necessary to add more doses where longer operating time is needed. However, an operation has to be discontinued in some cases when lidocaine fails

to provide enough duration of action, therefore limiting its use in some types of surgeries.

Bupivacaine, introduced in 1963, is an amide like lidocaine. However, it is much more lipid soluble, 5 conferring a different spectrum of clinical properties. It has a slower onset (10-15 minutes) and a much longer duration of action than lidocaine, as long as 24 hours when used for peripheral nerve block. Bupivacaine may produce fatal cardiovascular toxicity, central nervous 10 system toxicity, and cardiac arrhythmia. Anxiety, tinnitus, cardiac arrhythmias, coma, convulsions and delayed respiratory arrest may occur when it is administered intravenously. Particularly in ophthalmic applications, while bupivacaine will produce excellent 15 postoperative analgesia, residual diplopia will be experienced by up to 70% of patients next morning. On the other hand, its immobilizing action is inferior to that of other local anesthetics, such as lidocaine.

#### 20 Tetrodotoxin and Saxitoxin Formulation and Dosages:

For use in nerve block, tetrodotoxin and/or saxitoxin is typically administered in an aqueous solution. Typically, the active ingredient tetrodotoxin or saxitoxin is formulated into purified water or a 25 physiological saline solution as a major vehicle. However, it will be appreciated that the clinical formulation can contain other components, including, but not restricted to, buffering means to maintain or adjust pH, such as acetate buffers, citrate buffers, phosphate 30 buffers and borate buffers. Administration of



tetrodotoxin has been well studied in a number of animal species. The half-lethal dose for rats by intramuscular injection is between 11 to 18  $\mu\text{g}/\text{kg}$ , and that for human is estimated to be about 500  $\mu\text{g}/\text{kg}$ .

5        In one embodiment, the effective dose of tetrodotoxin or saxitoxin is administered from a formulation containing tetrodotoxin or saxitoxin at a concentration of between 0.01 mM to 1 mM (0.0033 to 0.33 mg per ml), preferably 0.03 mM to 0.3 mM (0.01 to 0.1 mg  
10 per ml). Up to 10 ml can be administered over a period of 10 to 15 minutes in 3 to 4 doses to obtain a local block. Typically, up to four ml can be injected in the first dose, then 2 to 3 ml can be administered in a second dose. The total amount of TTX administered should  
15 not exceed 100  $\mu\text{g}$ . The amount of TTX administered is preferably from 0.5 to 100  $\mu\text{g}$ , more preferably from 10 to 50  $\mu\text{g}$ . Such administration causes a nerve block effect for up to 6 hours, but preferably for 0.25 to 2 hours.

20        In this application, tetrodotoxin is typically formulated in a vehicle having a pH of between 3.5 to 8.0.

In this application, the pharmaceutical composition does not produce toxic effects or any obvious deleterious side effects.

25        In the experiments performed in support of the present invention, described above, a 50  $\mu\text{L}$  aliquot of 0.03 mM to 0.3 mM tetrodotoxin was administered by retrobulbar injection to rabbits' eyes. This corresponds to a dose of between 0.5-5  $\mu\text{g}$  of tetrodotoxin. These  
30 doses are well below the lethal oral human dose and give

a sufficient safety margin to allow for any differences in systemic absorption between local and intramuscular administration.

It will be appreciated that the dosage and concentration of tetrodotoxin or saxitoxin administered is determined on an individual basis, with consideration given to such factors as age and body weight of the patient, as well as to the route of administration and the clinical analgesic and anesthetic requirements. Other compounds useful in the present invention can be administered without the side effects described above for lidocaine and bupivacaine.

#### 15 **EXAMPLES**

The following examples illustrate the methods and compositions of the invention, but are in no way intended to limit the invention.

20 **Animals:** New Zealand white rabbits, purchased from the Animal Center of Beijing University, Beijing, P.R.China.

**Materials:** Tetrodotoxin substance, purity 97.8%, batch no. 000724-1, provided by Nanning Maple Leaf Pharmaceutical Co., Ltd. (Nanning, Guangxi, P.R. China).

##### 1. Preliminary toxicity study

Rabbits were randomly divided into 5 groups of 5-6 each.

30 Signs of convulsion, rigidity and death were observed at various times after the animals were injected TTX at 250 µg, 125 µg and 25 µg into the retrobulbar

area. Those given TTX at 2.5  $\mu$ g indicated local anesthesia to some extent. One animal in this group demonstrated conjunctival congestion, hydrops (++) and lacrimation in the TTX-treated eye, showed asthma for 1.5 hours and mitigated without intervention. No significant abnormalities were observed in other animals of the same group, neither was local anesthesia observed in the eyes treated with solvent alone.

Based upon the results, the safe dose levels in rabbits were determined to be up to about 2.5  $\mu$ g.

## 2. Efficacy study: Local Anesthesia by Retrobulbar injection of TTX

### Method

The experimental animals were randomly divided into groups of 6, half male and half female. The eyelashes of the animals were cut off prior to testing so as to avoid misjudgment due to mistaken contact with the eyelash.

The rabbits were immobilized in special holding boxes for experimental use. To each animal, a 50  $\mu$ L aliquot of solvent control was injected into the retrobulbar area of the left eye, and a 50  $\mu$ L aliquot of TTX or lidocaine hydrochloride at various concentrations was injected into the right eye. Corneal sensation was tested with a 5-0 silk suture. The cornea was mechanically stimulated three times (similar to previous rabbit model of corneal anesthesia reported in Maurice D M, Singh T., The absence of corneal toxicity with low-level topical anesthesia. Am J Ophthalmol. 99:691-696. (1985)). The rabbit's response was graded in the following fashion: no blink=1; partial

blink without full eyelid closure=2; full blink=3. Thus, a score of 3 indicates full responsiveness and a score of 1 indicates full local anesthesia. The highest anesthesia score of the 3 tests was recorded for each time point.

5 Corneal sensation was tested prior to administration of drugs and again at 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 1 hour, 2 hours, 3 hours and 10 hours.

10 Slit lamp biomicroscopy was performed with and without fluorescein stain from impregnated strips moistened with sodium salt solution at 12 and 24 hours after topical administration. The condition of cornea epithelium after dosing was assessed.

15 Indirect ophthalmoscopy was conducted to assess the condition of the ocular fundus. General examination of the animals was performed within one week after dosing.

Retinal toxicity (or effect on the retinal function) by TTX was evaluated by an electroretinogram at 24 hours after dosing. The method was as follows: complete  
20 platycoria was obtained by applying 1% tropine amide, and the eyes were subjected to darkness for 30 minutes. Ketamine at 0.15 mL/kg was injected intramuscularly prior to measurement. Topical anesthesia was obtained by administering 0.4% Beroxil. Skin electrodes were used as  
25 the reference and the ground, located subcutaneously in the forehead and the ear root. A cornea contact lens was used as the recording electrode, attached to the center of the cornea with 0.5% methyl fiber. The magnitude of the b wave was determined by the average results of three  
30 tests by stimulating with a single flash each time.

The animals were sacrificed by injecting air intravenously one week after dosing. Optical microscopy and transmission electron microscopy were performed subsequently.

5

#### Results:

Rabbits were randomly divided into 6 groups of 3xx/3xy. Signs of convulsion, rigidity and death were observed in the animals treated with TTX at 10 µg. 10 Animals given TTX at 5 µg, 2.5 µg, 1 µg and 0.5 µg showed local anesthesia in the treated eyes to various extents. While a weak effect was observed with TTX at 0.5 µg, the higher dose of TTX of 5 µg produced a long-lasting local anesthesia of approximately 6 hours.

#### 15 • Ophthalmic and general examinations:

Prior to and at 12 and 24 hours after topical administration, slit lamp biomicroscopy was performed with and without fluorescein stain from impregnated strips moistened with sodium salt solution on the 20 surviving animals. Indirect ophthalmoscopy was also performed. No significant abnormalities were observed. TTX onset and duration of action are shown in Figure 1.

#### • Electroretinogram (ERG)

Retinal toxicity (or effect on retinal function) by 25 TTX was evaluated with ERG at 24 hours after dosing. No significant differences in the magnitude of ERG b wave were found between the eyes treated with TTX at 2.5 µg or lower doses and their controls. Neither were differences found between those treated with lidocaine at 1000 µg or 30 lower doses and their controls. However, those treated

with TTX at 5  $\mu$ g were observed to have a lower ERG b. magnitude than their controls, showing a certain retinal toxicity at this dose level.

- General examination

5 No changes of food-taking pattern, movement, respiration or alertness were found in the majority of the animals treated with TTX at 5  $\mu$ g or less. One animal given TTX at 1  $\mu$ g had a seizure of asthma that lasted 25 minutes and mitigated without intervention. Another  
10 animal given TTX at 1  $\mu$ g appeared paralyzed in the hind limbs the next morning after administration, presumably resulting from improper injection operation as the retrobulbar area of a rabbit approximates the cranial cavity.

- 15 • Optic and electron microscopy

No obvious pathological changes in the retina were found in the animals treated with less than 5  $\mu$ g TTX during optic and transmission electron microscopy. Of the animals given TTX at 5  $\mu$ g, the membranes in the outer  
20 segments of photoreceptor cells became disorderly and thinned, the formation of mitochondria became disorderly, the number of phagosomes increased in the pigment epithelium cells, the number of outer nuclear layer cells decreased and vacuolar degeneration was observed.

25

### Conclusion:

The test results demonstrated that TTX can produce significant local anesthesia by retrobulbar injection into rabbit eyes. The durations of action were 0.37, 2.0,  
30 2.7 and 5.7 hours when TTX was given at doses of 0.5,

1.0, 2.5 and 5.0  $\mu\text{g}$ , respectively. In the control group, lidocaine at the dose of 1000  $\mu\text{g}$  produced local anesthesia with a duration of action of 0.34 hour. These results evidenced that TTX produces much more potent  
5 local anesthesia by retrobulbar injection than does lidocaine, an anesthetic commonly used in current clinical practice.

On the other hand, these studies showed that TTX had a slower onset than lidocaine. While an onset of 1.94  
10 minutes was observed at the dose level of lidocaine of 1000  $\mu\text{g}$ , the onset times for TTX were 9.65, 7.30, 5.19, 4.30 and 3.80 minutes at doses of 0.5, 1.0, 2.5, 5.0 and 10  $\mu\text{g}$ , respectively. This suggests that the onset of TTX is clearly dose-dependent: the onset time decreases when  
15 the dose increases.

Retrobulbar injection of TTX at 10  $\mu\text{g}$  and above caused death in rabbits at various times. TTX at 5  $\mu\text{g}$  produced retinal toxicity, whereas TTX at 2.5  $\mu\text{g}$  and under was not observed to produce any toxicity in rabbit  
20 eyes. Solvent control (sodium citrate buffer, pH 4.3), even though acidic, did not generate any pronounced stimulation to rabbit eyes.

**References:**

Various articles of the scientific periodical and patent literature are cited herein. Each such article is hereby incorporated by reference in its entirety for all purposes by such citation.

- [1] Monheim, L., Local Anesthesia and Pain Control in Dental Practice, 2nd. Edit. C.V. Mosby Co. 1961.
- 10 [2] Varvinski et al., Anaesthesia for Ophthalmic Surgery Part 1: Regional Techniques, Update in Anesthesia, Issue 6, 1996.
- [3] Ritchie J.M., Green N.M., "Local Anesthetics", pp. 300-302 in Gilman A.G., Goodman L.S., Gilman A., et al. (eds), The Pharmacological Basis of  
15 therapeutics, 6<sup>th</sup> Ed. C. 1980 by Macmillan, New York, NY.
- [4] Iliff N.T., Complications in Ophthalmic Surgery, pp. 28-34, c. 1983 by Churchill Livingstone Inc., New York, NY.
- 20 [5] Hatt Martin, Ophthalmic Plastic and Reconstructive Surgery, c. 1986 by Thieme, New York, NY.
- [6] Lawrence Halpern, "Local Anesthetics", Pharmacology vol. 435, pp. 117-126, Winter Quarter 2000.



**CLAIMS**

We claim:

1. A method of producing local analgesia or  
5 anesthesia in a nerve tissue region of a mammal  
experiencing pain caused by damage to or stimulation of a  
nerve tissue, comprising locally administering to the  
nerve tissue region of the mammal an anesthetically or  
analgesically effective dose of a pharmaceutical  
10 composition comprising a compound that binds to the SS1  
or SS2 subunit of a sodium channel and a pharmaceutically  
suitable vehicle;

wherein the nerve tissue region comprises:

(i) the peribulbar nerve and its distribution or a  
15 part thereof;

(ii) the retrobulbar nerve and its distribution or a  
part thereof;

(iii) the whole or a part of cranial nerve III, IV  
or V and the distribution thereof;

20 (iv) a ciliary ganglion and the whole or a part of  
the distribution thereof.

2. The method of claim 1, wherein the method  
of administration comprises administering the  
pharmaceutical composition to the intracone space by  
25 retrobulbar injection.

3. The method of claim 1, wherein the method  
of administration is peribulbar injection.

4. The method of claim 1, wherein the  
compound that binds to the SS1 or SS2 subunit of a sodium  
30 channel is tetrodotoxin.

5. The method of claim 4, wherein the effective dose is administered at a concentration of tetrodotoxin of from 0.01 mM to 10 mM.

6. The method of claim 4, wherein the effective dose is administered at a concentration of tetrodotoxin of from 0.03 mM to 3 mM.

7. The method of claim 1, wherein the effective dose of tetrodotoxin can produce local anesthesia or analgesia in the nerve tissue region for a period of 0.5 hour to 6 hours.

8. The method of claim 1, wherein the pharmaceutically suitable vehicle has a pH from 3 to 8.

9. The method of claim 8, wherein the pharmaceutically suitable vehicle has a pH from 4.5 to 7.5.

10. The method of claim 1, wherein the composition further comprises at least one auxiliary acidic solvent selected from dilute acetic acid, dilute hydrochloric acid and dilute citric acid.

11. The method of claim 1, wherein the composition further comprises at least one pH buffer selected from an acetate buffer, a citrate buffer, a phosphate buffer, a borate buffer.

12. The method of claim 1, wherein the composition comprises at least one compound that is tetrodotoxin, anhydrotetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin, ethoxytetrodotoxin, deoxytetrodotoxin or tetrodonic acid.

13. The method of claim 1, wherein the compound that binds to the SS1 or SS2 subunit of a sodium channel is saxitoxin.

14. The method of claim 13, wherein the effective dose is administered at a concentration of saxitoxin of from 0.01 mM to 10 mM.

15. The method of claim 13, wherein the saxitoxin is a compound comprising a tetrahydropurine moiety composed of two guanidine units fused together in a stable azaketal linkage, having a molecular formula  $C_{10}H_{17}N_7O_4$ .

## Abstract

The present invention relates to a method of obtaining local anesthesia and analgesia to the nerve tissue region of a mammal by administration of an effective dose of sodium channel blocking compounds, including tetrodotoxin and/or saxitoxin and derivatives thereof, in a pharmaceutically suitable vehicle.

# THE MERCK INDEX

AN ENCYCLOPEDIA OF  
CHEMICALS, DRUGS, AND BIOLOGICALS

TWELFTH EDITION

Susan Budavari, *Editor*  
Maryadele J. O'Neil, *Senior Associate Editor*  
Ann Smith, *Associate Editor*  
Patricia E. Heckelman, *Assistant Editor*  
Joanne F. Kinneary, *Assistant Editor*

*Published by*  
*Merck Research Laboratories*  
*Division of*

**MERCK & CO., INC.**

Whitehouse Station, NJ

1996

**BEST AVAILABLE COPY**

This material may be protected  
by copyright law (17 U.S.C.).

Whitehouse Station, N.J.  
U.S.A.

1st Edition—1889  
2nd Edition—1896  
3rd Edition—1907  
4th Edition—1930  
5th Edition—1940  
6th Edition—1952  
7th Edition—1960  
8th Edition—1968  
9th Edition—1976  
10th Edition—1983  
11th Edition—1989

Library of Congress Catalog  
Card Number 89-60001  
ISBN Number 0911910-12-3

**BEST AVAILABLE COPY**

Copyright © 1996 by MERCK & CO., INC.  
All rights reserved. Copyright under the Universal Copyright Convention  
and the International Copyright Convention.  
Copyright reserved under the Pan-American Copyright Convention.

Printed in the U.S.A.

With the Twentieth century of publication of disciplinary encyclopedias published in 1888, education over two the text contains biochemists, tion of interest of disciplines mind, but the lence in science


This edition, which more than doubles the number of articles, covers over 200 new and another 1,000 traditional 1,000 almost 1,000 hundred des

A number  
lished in 19  
chemical str  
chemical de  
scriptors ha  
readership,  
1983 in the  
of Chemical  
panded. Se  
some of the  
and immu

In recog  
reference v  
major onli  
which is b

Compar  
unparallele  
ronment, 1  
refer to Th  
by Merck  
the traditio

gan-10,17-diol; raupine.  $C_{19}H_{30}O_7$ , 73.52%, H 7.14%, N 9.03%, O 10.33% (Benth.). *Helv. Chim. Acta* 36, 1143 (1953); *ibid.* 40, 508 (1957); *France* 1957, 610; Biemann, *ibid.* 1961. Stereochemistry: Barr, Ohashi *et al.*, *Tetrahedron* 19,




ethanol, long plates from acetone (c = 0.5 in pyridine). uv max: 218, 277.5 nm (log  $\epsilon$  4.2, 1.83). One gram dissolves in 250 ml boiling methanol, insol in chloroform.  $CH_2Cl_2$ , needles from alcohol.

Root of *Smilax aristolochiae* Schlecht. (Mexican Sarsaparilla). *Helv. Chim. Acta* 36, 1143 (1953); *ibid.* 40, 508 (1957); *France* 1957, 610; Biemann, *ibid.* 1961. Stereochemistry: Barr, Ohashi *et al.*, *Tetrahedron* 19,

Pharmaceutic aid (flavor).

**8528. Sassafras.** Saxifrage; ague tree; cinnamon wood; saloop. Bark of root of *Sassafras albidum* (Nutt.) Nees [*S. virgifolium* (Salisb.) Kuntze, *S. officinale* Nees & Eberm.], Lauraceae. *Habit.* North America. *Constit.* Root: ~2% volatile oil. Bark of root: 6-9% volatile oil; sassafrid, wax. *USE:* Aromatic, flavoring agent. *THERAP CAT:* Sudorific.




from acetone, mp 199-199.5° (c = 0.5 in  $CHCl_3$ ). uv spectrum: 218, 277.5 nm (log  $\epsilon$  4.2, 1.83). One gram dissolves in 250 ml boiling methanol, insol in chloroform.  $CH_2Cl_2$ , needles from alcohol.

**8529. Sassy Bark.** Saucy bark; Mancona bark; ordeal bark; red-water tree bark; casca bark; Saxon bark; doom bark; teli; bondou. Bark of *Erythrophloeum guineense* G. Don, Leguminosae. *Habit.* Central and Western Africa. *Constit.* Erythrophloeine, tannin, resin.

**8530. Satumomab.** B72.3; CYT-099. Murine monoclonal antibody (MAb) of the IgG<sub>1</sub> subclass that targets a high molecular weight tumor-associated glycoprotein, TAG-72, expressed on the surface of certain human colon, breast and ovarian carcinoma cell lines. Prep and characterization of MAb: D. Colcher *et al.*, *Proc. Nat. Acad. Sci. USA* 78, 3199 (1981); J. Schlom *et al.*, U.S. pat. 4,612,282 (1986 to USA Secy. Dept. Health Human Services). Pharmacokinetics of <sup>125</sup>I-labeled MAb: B. A. Brown *et al.*, *Cancer Res.* 47, 1149 (1987). Clinical studies of immunoscintigraphy in colorectal cancer: B. D. Collier *et al.*, *Radiology* 185, 179 (1992); in ovarian cancer: E. A. Surwit *et al.*, *Gynecol. Oncol.* 48, 285 (1993). Review of prep and diagnostic use: R. T. Maguire *et al.*, *Cancer* 72, 3453-3462 (1993). Book: *Diagnosis of Colorectal and Ovarian Carcinoma*, R. T. Maguire, D. Van Nostrand, Eds. (Marcel Dekker, Inc., New York, 1992) 237 pp.

**8531. Saunders, Red.** Red sandalwood; ruby wood. Heartwood of *Pterocarpus santalinus* L. f., Leguminosae. *Habit.* East Indies. *Constit.* Santalin (santalinic acid), santal pterocarpin, tannin. *USE:* For coloring tinctures and similar medicinal preps; formerly used as a dye.

aceae: von Euw *et al.*, *Festschrift Prof. Paul Casparis* (Zürich, 1949) p 178; Buzas *et al.*, *Helv. Chim. Acta* 33, 465 (1950); Rothrock *et al.*, *J. Am. Chem. Soc.* 72, 3827 (1950); von Euw, Reichstein, *Helv. Chim. Acta* 33, 1006 (1950); Taylor, *J. Chem. Soc.* 1952, 4832. Structural studies: Taylor, *Chem. & Ind. (London)* 1953, 62; Schindler, *Helv. Chim. Acta* 39, 375 (1956); Taylor, *J. Chem. Soc. (C)* 1966, 790. Revised structure: Fuhrer *et al.*, *Helv. Chim. Acta* 52, 616 (1969).



Crystallizes in various forms with different mps, but [according to Taylor, *J. Chem. Soc.* 1952, 4832] on recrystn from methanol all of these forms yield the one melting at 132-134°.  $[\alpha]_D^{25} +44.5^\circ \pm 2^\circ$  (c = 1.1683 in methanol);  $[\alpha]_D^{25} +49.5^\circ$  (methanol). uv max: 218, 277.5 nm (log  $\epsilon$  4.2, 1.83). Sol in water, methanol, chloroform.

Diacetate, crystals, mp 254-256° (corr).  $[\alpha]_D^{25} +24.2^\circ$  (chloroform).

Dibenzoate, cryst powder from methanol, mp 189° (Taylor, *loc. cit.*); mp 187-191° (micro-block, Rothrock *et al.*, *loc. cit.*);  $[\alpha]_D^{25} +30.7^\circ \pm 1^\circ$  (c = 1.301 in acetone). Sol in acetone; slightly sol in methanol.

**8528. Sassafras.** Saxifrage; ague tree; cinnamon wood; saloop. Bark of root of *Sassafras albidum* (Nutt.) Nees [*S. virgifolium* (Salisb.) Kuntze, *S. officinale* Nees & Eberm.], Lauraceae. *Habit.* North America. *Constit.* Root: ~2% volatile oil. Bark of root: 6-9% volatile oil; sassafrid, wax. *USE:* Aromatic, flavoring agent. *THERAP CAT:* Sudorific.

**8529. Sassy Bark.** Saucy bark; Mancona bark; ordeal bark; red-water tree bark; casca bark; Saxon bark; doom bark; teli; bondou. Bark of *Erythrophloeum guineense* G. Don, Leguminosae. *Habit.* Central and Western Africa. *Constit.* Erythrophloeine, tannin, resin.

**8530. Satumomab.** B72.3; CYT-099. Murine monoclonal antibody (MAb) of the IgG<sub>1</sub> subclass that targets a high molecular weight tumor-associated glycoprotein, TAG-72, expressed on the surface of certain human colon, breast and ovarian carcinoma cell lines. Prep and characterization of MAb: D. Colcher *et al.*, *Proc. Nat. Acad. Sci. USA* 78, 3199 (1981); J. Schlom *et al.*, U.S. pat. 4,612,282 (1986 to USA Secy. Dept. Health Human Services). Pharmacokinetics of <sup>125</sup>I-labeled MAb: B. A. Brown *et al.*, *Cancer Res.* 47, 1149 (1987). Clinical studies of immunoscintigraphy in colorectal cancer: B. D. Collier *et al.*, *Radiology* 185, 179 (1992); in ovarian cancer: E. A. Surwit *et al.*, *Gynecol. Oncol.* 48, 285 (1993). Review of prep and diagnostic use: R. T. Maguire *et al.*, *Cancer* 72, 3453-3462 (1993). Book: *Diagnosis of Colorectal and Ovarian Carcinoma*, R. T. Maguire, D. Van Nostrand, Eds. (Marcel Dekker, Inc., New York, 1992) 237 pp.


**Indium <sup>111</sup>In satumomab pendetide, <sup>111</sup>In-CYT-103, monoclonal antibody B72.3-GYK-DTPA-In-111, B72.3-glycyl-tyrosyl-N-ε-diethylenetriaminopentaacetic acid-In-111, OncoScint.** *THERAP CAT:* <sup>111</sup>In-labeled form as diagnostic aid (radioactive tumor-targeting agent).

**8531. Saunders, Red.** Red sandalwood; ruby wood. Heartwood of *Pterocarpus santalinus* L. f., Leguminosae. *Habit.* East Indies. *Constit.* Santalin (santalinic acid), santal pterocarpin, tannin.

*USE:* For coloring tinctures and similar medicinal preps; formerly used as a dye.

**8532. Savin.** Young shoots of *Juniperus sabina* L., Cupressaceae. *Habit.* Europe, Northern Asia, North America south to New York, and Montana. *Constit.* 2-4% volatile oil, tannin, savinin, podophyllotoxin. Isolation and structure of savinin: Hartwell *et al.*, *J. Am. Chem. Soc.* 75, 235 (1953); Schrecker, Hartwell, *ibid.* 76, 4896 (1954). *THERAP CAT:* Emmenagogue. Anthelmintic. Antirheumatic.

**8533. Saxitoxin.** Mussel poison; clam poison; paralytic shellfish poison; gonyaulax toxin; STX.  $[C_{10}H_{17}N_7O_4]^{2+}$ . Powerful neurotoxin produced by the dinoflagellates *Gonyaulax catenella*, or *G. tamarensis*, the consumption of which causes the California sea mussel *Mytilus californianus*, the Alaskan butterclam *Saxidomus giganteus* and the scallop to become poisonous: Sommer *et al.*, *Arch. Pathol.* 24, 537, 560 (1937); Schantz *et al.*, *Can. J. Chem.* 39, 2117 (1961); Ghazarossian *et al.*, *Biochem. Biophys. Res. Commun.* 59, 1219 (1974). These poisonous shellfish have been connected to instances of toxic "red-tides" where the high concentrations of algae discoloring the water were of the *Gonyaulax* genus. Isolation and partial characterization: Schantz *et al.*, *J. Am. Chem. Soc.* 79, 5230 (1957); Mold *et al.*, *ibid.* 5235. Purification and biochemical data: Schantz *et al.*, *Biochemistry* 5, 1191 (1966); Schantz, *Ann. N.Y. Acad. Sci.* 90, 843 (1960). pKa values: R. S. Rogers, H. Rapoport, *J. Am. Chem. Soc.* 102, 7335 (1980). Toxicity: G. S. Wiberg, N. R. Stephenson, *Toxicol. Appl. Pharmacol.* 2, 607 (1960). Structural studies: Schuett, Rapoport, *J. Am. Chem. Soc.* 84, 2266 (1962); Wong *et al.*, *ibid.* 93, 4633, 7344 (1971). Revised structure: Schantz *et al.*, *ibid.* 97, 1238 (1975); Bordner *et al.*, *ibid.* 97, 6008 (1975). Pharmacology including study of sodium transport inhibition: Cheymol *et al.*, *Arch. Int. Pharmacodyn. Ther.* 174, 393 (1968); Evans, *Brit. Med. Bull.* 25, 263 (1969). Stereospecific total synthesis of dl-saxitoxin: H. Tanino *et al.*, *J. Am. Chem. Soc.* 99, 2818 (1977); Y. Kishi, *Heterocycles* 14, 1477 (1980). Reviews: Kao, *Pharmacol. Rev.* 18, 997 (1966); Kao, *Fed. Proc. Fed. Am. Soc. Exp. Biol.* 31, 1117 (1972); Narahashi, *ibid.* 1124, Evans, *Int. Rev. Neurobiol.* 15, 83 (1972); Y. Shimizu in *Progress in the Chemistry of Natural Products* vol. 45, W. Herz *et al.*, Eds. (Springer-Verlag, New York, 1984) pp 239-246. See also Brevetoxins.



Dihydrochloride, white, hygroscopic solid. pKa in water: 8.24, 11.60.  $[\alpha]_D^{25} +130^\circ$ . Very sol in water, methanol; sparingly sol in ethanol, glacial acetic acid. Practically insol in lipid solvents. Stable in acid solns; decomposes rapidly in alkaline media. Boiling 3-4 hrs at pH 3 causes loss of activity. LD<sub>50</sub> in mice (μg/kg): 10 i.p.; 263 orally; 3.4 i.v. (Wiberg, Stephenson).

*USE:* As a tool in neurochemical research.

**8534. SBR Rubber.** Styrene-butadiene rubber; GR-S; Government Rubber Styrene. General-purpose synthetic rubbers that were originally produced in government owned plants as GR-S. They are copolymers obtained by the polymerization of butadiene and styrene in a ratio of approx 3:1. The chains contain a random sequence of the two monomers. Very similar in composition to Buna S, Kraton, Solprene, Stereon. Review: P. Schneider *et al.*, in Ullmann, *Encyklopädie der technischen Chemie*, 3 Aufl., Bd. IX (München-Berlin, 1957) p 331; M. Morton, *Introduction to Rubber Technology* (Reinhold, 1959) pp 56 and 256-284; R. G. Bauer in Kirk-Othmer *Encyclopedia of Chemical Technology* vol. 8 (Wiley-Interscience, New York, 3rd ed., 1979) pp 608-625.

*USE:* In tires, adhesives, chewing gum.

**8535. Scabiolide.** 2,3-Dihydroxy-2-methylpropanoic acid 6-[(acetyloxy)methyl]-2,3,4a,4,7,8,11,11a-octahydro-10-